CVS Health’s Accordant gets NCQA disease management accreditation for 18 conditions
WOONSOCKET, R.I. — CVS Health company Accordant has received NCQA Patient and Practitioner Oriented Disease Management Accreditation, the company announced Wednesday. The disease management accreditation was given for a number of Accordant’s programs providing services to patients with rare chronic disease and other conditions on behalf of health plans, government-sponsored plans, labor groups, employers and third-party administrators, and covers 18 conditions, including epilepsy, Parkinson’s disease, ALS, HIV, Crohn’s disease and others.
"We are pleased to receive this important accreditation from NCQA, which further validates our approach to providing high-quality and comprehensive disease management care and support for our patients with these rare, chronic conditions," CVS Specialty EVP Dr. Alan Lotvin said. "For more than 20 years, Accordant has been providing highly specialized care to patients to help them better manage their condition, improve health outcomes and help avoid unnecessary medical costs for both patients and payers."
CVS Health said that the accreditation indicates that a disease management program is dedicated to providing support, education and other help necessary to facilitating good outcomes and care. The standards are designed to help organizations achieve the best performance, increase adherence to care guidelines and create an environment for continued improvement, the company said.
"Our Accordant nurses are specially trained to provide disease-specific support to help prevent complications, improve our patients' total health and enhance quality of life," Accordant president Trip Hofer said. "In addition, Accordant's unique, proactive disease management approach helps anticipate shifts in patient needs as their condition progresses over time, which is integral in ensuring each patient receives the most clinically appropriate care and support along their health care journey."
Accordant has maintained NCQA disease management accreditations since 2003, and was awarded case management accreditation in 2016. Accordant’s disease management programs are led by specialized and trained nurses who provide comprehensive patient education, medication and symptom management, as well as coordination of patient care with other healthcare providers.
CVS Health said that its CVS Specialty division is the largest specialty pharmacy, providing advanced clinical services for eligible patients who require treatment for rare or complex conditions.
"NCQA's Disease Management Accreditation program is thorough and rigorous,” NCQA president Margaret O'Kane said. “It's designed to highlight only those programs that truly improve chronic care.’
Rite Aid to leverage RangeMe tech platform for product sourcing
SAN FRANCISCO — Rite Aid plans to leverage RangeMe, an online platform that streamlines new product discovery between suppliers and retailers, to scale its product innovation efforts.
“We strive to provide a tremendous in-store experience for our customers and that starts with our product offerings,” said Bill Bergin, Group VP of health and beauty at Rite Aid. “With RangeMe, we can now scale our discovery efforts and continue to source products that are unique and meaningful for our customers.”
Rite Aid’s category buying teams will now have faster access to source trending consumer-ready products, according to RangeMe.
“Consumers are open to trying new brands as trends are becoming the primary driver of purchasing decisions,” said Nicky Jackson, founder and CEO at RangeMe. “RangeMe looks forward to working with the Rite Aid team and supporting them in their efforts to bring unique products to their customers and differentiate their brand.”
San Francisco–based RangeMe offers buyers a platform that, according to RangeMe, gives suppliers increased control of the marketing of their products as well as greater access to retail buyers. In the past year, RangeMe has grown to more than 70,000 suppliers and more than 250,000 active products across all categories.
Octapharma gets FDA approval for new product strengths of NUWIQ
HOBOKEN, N.J. — Octapharma USA today announced that the U.S. Food and Drug Administration has approved new product strengths for NUWIQ. The move potentially reduces the number of vials needed for hemophilia A patients, the company said.
The agency approved new-single dose vial strengths of 2500-, 3000- and 4000-IU, which will be available for ordering in the United States starting Sept. 2017. These new vial strengths will be provided in addition to the already available strengths of 250-, 500-, 1000- and 2000 IU. NUWIQ is the only recombinant Factor VIII providing patients a wide array of vials with the lowest diluent volume of 2.5ml, the company added.
NUWIQ anti-hemophilic factor (recombinant) lyophilized powder for solution for intravenous injection is a recombinant anti-hemophilic factor indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes.
“The new vial options will benefit patients, physicians and healthcare professionals by providing greater treatment flexibility and convenience,” said Flemming Nielsen, Octapharma USA president. “The variety of vial options will be particularly beneficial to patients who previously may have needed more than one of the lower-strength vials. The availability of the new vial strengths further illustrates Octapharma’s unwavering commitment to the Hemophilia A community.”
The additional vial strengths offer benefits beyond potentially reducing the number of vials used per patient. The new vial sizes may benefit heavier patients who could use fewer product vials and, in some cases, just one vial, according to the company. More NUWIQ vial options will increase dosing flexibility by allowing physicians to select various vial combinations to align closer to the prescribed dose. The new vial sizes could be particularly beneficial to patients treated with NUWIQ utilizing a pharmacokinetic-guided personalized prophylaxis approach — wherein the dosing is further optimized compared with standard prophylaxis.